Companies › SetPoint Medical
1 active drug program in 1 registered trial: 1 Phase 3; Immunology; next expected readout Oct 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| SetPoint System (vagus nerve stimulator) Vagus nerve stimulation | – | Phase 3 | Rheumatoid Arthritis | Oct 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04539964 | SetPoint System (vagus nerve stimulator) | Phase 3 | Rheumatoid Arthritis | Immunology | Oct 2027 |
No annotated target.
–
Pharvaris Netherlands AUG Therapeutics Lynk Pharmaceuticals Fujian Mindong Rejuvenation Pharmaceutical Jiangsu Genscend Biopharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.